Report cover image

Ankylosing Spondylitis Treatment Drug Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 131 Pages
SKU # APRC20352545

Description

Summary

According to APO Research, The global Ankylosing Spondylitis Treatment Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Ankylosing Spondylitis Treatment Drug include UCB, Abbott, Takeda, Eisai, Guojian Pharmaceutical, Celgen Pharm, Johson & Johson, Novartis and Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Ankylosing Spondylitis Treatment Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ankylosing Spondylitis Treatment Drug.
The Ankylosing Spondylitis Treatment Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Ankylosing Spondylitis Treatment Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Ankylosing Spondylitis Treatment Drug Segment by Company

UCB
Abbott
Takeda
Eisai
Guojian Pharmaceutical
Celgen Pharm
Johson & Johson
Novartis
Merck
Maibo Pharma
Pfizer
Hisun Pharm
Bio-Thera Solutions
Amgen
Abbive
Mitsubishi Tanabe
Ankylosing Spondylitis Treatment Drug Segment by Type

Non-steroidal Anti-inflammatory Drugs
Inhibitor
Ankylosing Spondylitis Treatment Drug Segment by Application

Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Other
Ankylosing Spondylitis Treatment Drug Segment by Application

Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Other
Ankylosing Spondylitis Treatment Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ankylosing Spondylitis Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ankylosing Spondylitis Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ankylosing Spondylitis Treatment Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Ankylosing Spondylitis Treatment Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

131 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Ankylosing Spondylitis Treatment Drug by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Non-steroidal Anti-inflammatory Drugs
2.2.3 Inhibitor
2.3 Ankylosing Spondylitis Treatment Drug by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Retail Pharmacy
2.3.3 Online Pharmacy
2.3.4 Hospital Pharmacy
2.3.5 Other
2.4 Assumptions and Limitations
3 Ankylosing Spondylitis Treatment Drug Breakdown Data by Type
3.1 Global Ankylosing Spondylitis Treatment Drug Historic Market Size by Type (2020-2025)
3.2 Global Ankylosing Spondylitis Treatment Drug Forecasted Market Size by Type (2026-2031)
4 Ankylosing Spondylitis Treatment Drug Breakdown Data by Application
4.1 Global Ankylosing Spondylitis Treatment Drug Historic Market Size by Application (2020-2025)
4.2 Global Ankylosing Spondylitis Treatment Drug Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Ankylosing Spondylitis Treatment Drug Market Perspective (2020-2031)
5.2 Global Ankylosing Spondylitis Treatment Drug Growth Trends by Region
5.2.1 Global Ankylosing Spondylitis Treatment Drug Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Ankylosing Spondylitis Treatment Drug Historic Market Size by Region (2020-2025)
5.2.3 Ankylosing Spondylitis Treatment Drug Forecasted Market Size by Region (2026-2031)
5.3 Ankylosing Spondylitis Treatment Drug Market Dynamics
5.3.1 Ankylosing Spondylitis Treatment Drug Industry Trends
5.3.2 Ankylosing Spondylitis Treatment Drug Market Drivers
5.3.3 Ankylosing Spondylitis Treatment Drug Market Challenges
5.3.4 Ankylosing Spondylitis Treatment Drug Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Ankylosing Spondylitis Treatment Drug Players by Revenue
6.1.1 Global Top Ankylosing Spondylitis Treatment Drug Players by Revenue (2020-2025)
6.1.2 Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Players (2020-2025)
6.2 Global Ankylosing Spondylitis Treatment Drug Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Ankylosing Spondylitis Treatment Drug Head Office and Area Served
6.4 Global Ankylosing Spondylitis Treatment Drug Players, Product Type & Application
6.5 Global Ankylosing Spondylitis Treatment Drug Manufacturers Established Date
6.6 Global Ankylosing Spondylitis Treatment Drug Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Ankylosing Spondylitis Treatment Drug Market Size (2020-2031)
7.2 North America Ankylosing Spondylitis Treatment Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Ankylosing Spondylitis Treatment Drug Market Size by Country (2020-2025)
7.4 North America Ankylosing Spondylitis Treatment Drug Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Ankylosing Spondylitis Treatment Drug Market Size (2020-2031)
8.2 Europe Ankylosing Spondylitis Treatment Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Ankylosing Spondylitis Treatment Drug Market Size by Country (2020-2025)
8.4 Europe Ankylosing Spondylitis Treatment Drug Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size (2020-2031)
9.2 Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size by Country (2020-2025)
9.4 Asia-Pacific Ankylosing Spondylitis Treatment Drug Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Ankylosing Spondylitis Treatment Drug Market Size (2020-2031)
10.2 South America Ankylosing Spondylitis Treatment Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Ankylosing Spondylitis Treatment Drug Market Size by Country (2020-2025)
10.4 South America Ankylosing Spondylitis Treatment Drug Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size (2020-2031)
11.2 Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size by Country (2020-2025)
11.4 Middle East & Africa Ankylosing Spondylitis Treatment Drug Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 UCB
12.1.1 UCB Company Information
12.1.2 UCB Business Overview
12.1.3 UCB Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.1.4 UCB Ankylosing Spondylitis Treatment Drug Product Portfolio
12.1.5 UCB Recent Developments
12.2 Abbott
12.2.1 Abbott Company Information
12.2.2 Abbott Business Overview
12.2.3 Abbott Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.2.4 Abbott Ankylosing Spondylitis Treatment Drug Product Portfolio
12.2.5 Abbott Recent Developments
12.3 Takeda
12.3.1 Takeda Company Information
12.3.2 Takeda Business Overview
12.3.3 Takeda Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.3.4 Takeda Ankylosing Spondylitis Treatment Drug Product Portfolio
12.3.5 Takeda Recent Developments
12.4 Eisai
12.4.1 Eisai Company Information
12.4.2 Eisai Business Overview
12.4.3 Eisai Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.4.4 Eisai Ankylosing Spondylitis Treatment Drug Product Portfolio
12.4.5 Eisai Recent Developments
12.5 Guojian Pharmaceutical
12.5.1 Guojian Pharmaceutical Company Information
12.5.2 Guojian Pharmaceutical Business Overview
12.5.3 Guojian Pharmaceutical Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.5.4 Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Product Portfolio
12.5.5 Guojian Pharmaceutical Recent Developments
12.6 Celgen Pharm
12.6.1 Celgen Pharm Company Information
12.6.2 Celgen Pharm Business Overview
12.6.3 Celgen Pharm Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.6.4 Celgen Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio
12.6.5 Celgen Pharm Recent Developments
12.7 Johson & Johson
12.7.1 Johson & Johson Company Information
12.7.2 Johson & Johson Business Overview
12.7.3 Johson & Johson Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.7.4 Johson & Johson Ankylosing Spondylitis Treatment Drug Product Portfolio
12.7.5 Johson & Johson Recent Developments
12.8 Novartis
12.8.1 Novartis Company Information
12.8.2 Novartis Business Overview
12.8.3 Novartis Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.8.4 Novartis Ankylosing Spondylitis Treatment Drug Product Portfolio
12.8.5 Novartis Recent Developments
12.9 Merck
12.9.1 Merck Company Information
12.9.2 Merck Business Overview
12.9.3 Merck Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.9.4 Merck Ankylosing Spondylitis Treatment Drug Product Portfolio
12.9.5 Merck Recent Developments
12.10 Maibo Pharma
12.10.1 Maibo Pharma Company Information
12.10.2 Maibo Pharma Business Overview
12.10.3 Maibo Pharma Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.10.4 Maibo Pharma Ankylosing Spondylitis Treatment Drug Product Portfolio
12.10.5 Maibo Pharma Recent Developments
12.11 Pfizer
12.11.1 Pfizer Company Information
12.11.2 Pfizer Business Overview
12.11.3 Pfizer Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.11.4 Pfizer Ankylosing Spondylitis Treatment Drug Product Portfolio
12.11.5 Pfizer Recent Developments
12.12 Hisun Pharm
12.12.1 Hisun Pharm Company Information
12.12.2 Hisun Pharm Business Overview
12.12.3 Hisun Pharm Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.12.4 Hisun Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio
12.12.5 Hisun Pharm Recent Developments
12.13 Bio-Thera Solutions
12.13.1 Bio-Thera Solutions Company Information
12.13.2 Bio-Thera Solutions Business Overview
12.13.3 Bio-Thera Solutions Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.13.4 Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Product Portfolio
12.13.5 Bio-Thera Solutions Recent Developments
12.14 Amgen
12.14.1 Amgen Company Information
12.14.2 Amgen Business Overview
12.14.3 Amgen Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.14.4 Amgen Ankylosing Spondylitis Treatment Drug Product Portfolio
12.14.5 Amgen Recent Developments
12.15 Abbive
12.15.1 Abbive Company Information
12.15.2 Abbive Business Overview
12.15.3 Abbive Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.15.4 Abbive Ankylosing Spondylitis Treatment Drug Product Portfolio
12.15.5 Abbive Recent Developments
12.16 Mitsubishi Tanabe
12.16.1 Mitsubishi Tanabe Company Information
12.16.2 Mitsubishi Tanabe Business Overview
12.16.3 Mitsubishi Tanabe Revenue in Ankylosing Spondylitis Treatment Drug Business (2020-2025)
12.16.4 Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Product Portfolio
12.16.5 Mitsubishi Tanabe Recent Developments
13 Report Conclusion
14 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.